This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) - ezetimibe plus statin in high risk patients with cardiovascular disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial)

  • study randomized 18,000 stabilized acute coronary syndrome patients (about 40% of them from North America) to either 40 mg simvastatin or 10 mg ezetimibe/40 mg simvastatin
    • patients who had LDLs higher than 79 mg/dL were up-titrated to 80 mg simvastatin
      • 27% of the simvastatin patients required higher doses as did 6% of the ezetimibe/simvastatin patients
    • patients were followed at 30 days and then every 4 months until the trial had accumulated 5,250 events, defined as MI, stroke, cardiovascular death, revascularization, or hospitalization for unstable angina


  • in high-risk patients, adding ezetimibe to statin therapy reduced LDL cholesterol by an average of 17 mg/dL (0.4 mmol/L) and reduced cardiovascular events compared with statin therapy alone

  • finding from the 18,000-patient IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) trial marks the first time that adding a nonstatin lipid-lowering therapy to a statin demonstrated a clinical benefit

  • niacin, fibrates, and CETP inhibitors added to statins have all failed to achieve a benefit
    • however this trial showed that ezetimibe plus simvastatin reduced the rate of cardiovascular death, myocardial infarction, or stroke by 2 percentage points (34.7% for simvastatin alone versus 32.7% for ezetimibe plus simvastatin) in IMPROVE-IT, which represented 270 fewer events over 7 years of follow-up

  • no statistically significant difference in cancer, muscle, or gallbladder-related events

  • treating 100 patients would prevent two events over a seven year period

  • at 1 year, the average LDL-C in the simvastatin arm was 69.9 mg/dL versus 53.2 mg/dL in the ezetimibe/simvastatin group. There was no difference in HDL-C, nor was there a difference in highly-sensitive CRP, which is considered a marker for increased risk of cardiovascular events

  • note that 42% of patients, regardless of treatment, stopped the study drug before the end of the trial

  • average age of patients was 64 and about a fourth were women. At baseline the average LDL-C was 95 mg/dL (approx 2.4 mmol/L)

  • this study is supportive of the the theory that the lower the LDL the better in terms of reduction of cardiovascular risk


  • AHA: IMPROVE-IT ((IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) - announcement of results of trial (November 17th 2014).

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.